ストックスクリーナーアプリを入手
0.398
4.68%
0.0178
アフターアワーズ：
.39
-0.008
-2.01%
前日終値:
$0.3802
開ける：
$0.38
24時間の取引高:
31,924
Relative Volume:
0.20
時価総額：
$1.78M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+13.75%
1か月 パフォーマンス:
-17.10%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.37
$0.40
1週間の範囲:
$0.3552
$0.4069
52週間の値動き範囲:
$0.3349
$1.04
Naya Biosciences Stock (NAYA) Company Profile
NAYA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NAYA
Naya Biosciences
|
0.398 | 1.78M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
134.95 | 234.06B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.39 | 154.06B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
387.92 | 148.02B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.17 | 115.71B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.76 | 42.91B | 5.72B | 4.17B | 490.10M | 6.97 |
Naya Biosciences (NAYA) 最新ニュース
NAYA Biosciences nominates five candidates for the Board - TipRanks
NAYA Biosciences Announces Nomination of New Board Members - GlobeNewswire
Maxim Group Upgrades NAYA Biosciences (NAYA) - MSN
NAYA Biosciences (NASDAQ:NAYA) Raised to Buy at Maxim Group - Defense World
NAYA Biosciences Raises $9.5M Amid Nasdaq Compliance Issues - TipRanks
NAYA Biosciences sets public offering at $0.70 per unit By Investing.com - Investing.com South Africa
Lakewood Ranch life sciences firm seeks to raise $9.5M through public offering - Business Observer
NAYA Stock Hits 52-Week Low at $0.62 Amid Market Challenges - Investing.com
NAYA Biosciences Announces Pricing of $9.5 Million Public Offering - GlobeNewswire
NAYA Biosciences sets public offering at $0.70 per unit - Investing.com
NAYA Biosciences Raises $9.5M in Public Offering to Fund Acquisition and Growth Plans - StockTitan
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
NAYA Biosciences expands oncology pipeline with new antibody By Investing.com - Investing.com Nigeria
NAYA Biosciences expands oncology pipeline with new antibody - Investing.com
NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody - GlobeNewswire
NAYA Biosciences Unveils NY-500, AI-Enhanced Cancer Antibody Outperforming Keytruda - StockTitan
NAYA (NAYA Biosciences) Long-Term Debt & Capital Lease Obli - GuruFocus.com
The horror of Saydnaya jail, symbol of Assad excesses - News- Graphic
INVO Bioscience : Expands its Presence in Eurasia with New Distribution Agreements to Commercialize the INVOcell In Vivo Fertilization System - Marketscreener.com
NAYA Biosciences files to sell $10M of units - Nasdaq
Grapevine December 15, 2024: Changing of the guard - The Jerusalem Post
NAYA Biosciences Inc. (NAYA) reports earnings - Quartz
NAYA (NAYA Biosciences) Profitability Rank : 2 (As of Jun. 2024) - GuruFocus.com
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
NAYA Biosciences to Present Translational Insights to - GlobeNewswire
NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewswire
INVO Bioscience, Inc. announced that it has received $0.275 million in funding - Marketscreener.com
INVO Bioscience Closes Wisconsin Fertility Institute Acquisition - Marketscreener.com
INVO Bioscience Closes Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel Invocell System for Use in the Treatment of Infertility - Marketscreener.com
INVO Bioscience, Inc. Announces Appointment of Pressly Ahammed as Director of International Business Development - Marketscreener.com
INVOcell Appoints Yve Lyppens as Director Business Development Asia Pacific - Marketscreener.com
INVO Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.com
INVO Bioscience, Inc. Announces Grand Opening of "Positib Fertility, an INVO Center" in Monterrey, Mexico on November 1, 2021 - Marketscreener.com
INVO Bioscience Announces the Appointment of Steve Shum as Chief Executive Officer - Marketscreener.com
NAYA Biosciences Announces Initiation of Phase 1/2a - GlobeNewswire
NAYA (NAYA Biosciences) Enterprise Value : $15.50 Mil (As of Oct. 25, 2024) - GuruFocus.com
Top Premarket Gainers - Marketscreener.com
NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma - The Manila Times
The court declared bankruptcy of MPG AgroProduction OÜ - The Manila Times
INVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 - Marketscreener.com
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC - Marketscreener.com
INVO Bioscience changes name, trading symbol after merger - Business Observer
INVO Bioscience confirms name change, new trading symbol following NAYA merger - TipRanks
INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences - The Manila Times
CERo Therapeutics, Inc. Provides Corporate Update - The Manila Times
INVO Bioscience (NASDAQ: INVO) Stock Sees Bullish Momentum on Merger News - DRP Journal
INVO Bioscience Completes Merger with NAYA Biosciences - TipRanks
Sarasota fertility company completes merger with bioscience firm - Business Observer
INVO Bioscience merges with NAYA, eyes oncology market - Investing.com
INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA) - The Manila Times
Sify Technologies announces the appointment of Ms. Padmaja Chunduru as Director on the Board - The Manila Times
Naya Biosciences (NAYA) 財務データ
Naya Biosciences (NAYA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.10%
0.57%
大文字化:
|
ボリューム (24 時間):